[go: up one dir, main page]

EA200300027A1 - METHOD OF TREATING CARDIOVASCULAR DISEASES - Google Patents

METHOD OF TREATING CARDIOVASCULAR DISEASES

Info

Publication number
EA200300027A1
EA200300027A1 EA200300027A EA200300027A EA200300027A1 EA 200300027 A1 EA200300027 A1 EA 200300027A1 EA 200300027 A EA200300027 A EA 200300027A EA 200300027 A EA200300027 A EA 200300027A EA 200300027 A1 EA200300027 A1 EA 200300027A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cardiovascular diseases
treating cardiovascular
mammal
vascular disease
disease
Prior art date
Application number
EA200300027A
Other languages
Russian (ru)
Inventor
Нил Иван Азролан
Сурендра Нэт Сейгал
Стивен Джей Эйдэлман
Original Assignee
Уайт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22789625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200300027(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Уайт filed Critical Уайт
Publication of EA200300027A1 publication Critical patent/EA200300027A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к способу лечения или профилактики заболевания сердечно-сосудистой системы, заболевания мозговых сосудов или заболевания периферических сосудов у млекопитающего, нуждающегося в этом, который включает в себя обеспечение указанному млекопитающему эффективного количества рапамицина.Отчет о международном поиске был опубликован 2002.05.10.The invention relates to a method for treating or preventing a disease of the cardiovascular system, cerebral vascular disease or peripheral vascular disease in a mammal in need thereof, which includes providing the mammal with an effective amount of rapamycin. An international search report was published 2002.05.10.

EA200300027A 2000-06-16 2001-06-14 METHOD OF TREATING CARDIOVASCULAR DISEASES EA200300027A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21211700P 2000-06-16 2000-06-16
PCT/US2001/019179 WO2001097809A2 (en) 2000-06-16 2001-06-14 Method of treating cardiovascular disease using rapamycin

Publications (1)

Publication Number Publication Date
EA200300027A1 true EA200300027A1 (en) 2003-06-26

Family

ID=22789625

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300027A EA200300027A1 (en) 2000-06-16 2001-06-14 METHOD OF TREATING CARDIOVASCULAR DISEASES

Country Status (19)

Country Link
US (1) US20020013335A1 (en)
EP (1) EP1292302A2 (en)
JP (1) JP2003535899A (en)
KR (1) KR20030010710A (en)
CN (1) CN1436076A (en)
AR (1) AR028959A1 (en)
AU (2) AU2001268446B2 (en)
BR (1) BR0111601A (en)
CA (1) CA2412636A1 (en)
CZ (1) CZ20024115A3 (en)
EA (1) EA200300027A1 (en)
HU (1) HUP0301244A3 (en)
IL (1) IL153405A0 (en)
MX (1) MXPA02012410A (en)
NO (1) NO20026008D0 (en)
NZ (1) NZ523114A (en)
PL (1) PL365455A1 (en)
WO (1) WO2001097809A2 (en)
ZA (1) ZA200300418B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2269603B1 (en) 2001-02-19 2015-05-20 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with exemestane
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
EP2407473A3 (en) 2002-02-01 2012-03-21 ARIAD Pharmaceuticals, Inc Method for producing phosphorus-containing compounds
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
BR0313024A (en) 2002-07-30 2005-07-12 Wyeth Corp Parenteral formulations containing a rapamycin hydroxyester
WO2004026280A2 (en) * 2002-09-17 2004-04-01 Wyeth Granulate formulation of the rapamycin ester cci-779
AU2003293529A1 (en) 2002-12-16 2004-07-29 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
AR042938A1 (en) 2003-02-06 2005-07-06 Wyeth Corp USE OF CCI-779 IN THE TREATMENT OF HEPATIC FIBROSIS
US7728033B2 (en) 2003-05-05 2010-06-01 Clinigene International Private Limited Mycophenolate mofetil in diabetic nephropathy
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
DE102004019845A1 (en) * 2004-03-29 2005-10-20 Krka Tovarna Zdravil D D Solid composition used as acetyl cholinesterase inhibitor comprises perindopril, microcrystalline cellulose, inorganic carbonate and other components
US20050232965A1 (en) * 2004-04-15 2005-10-20 Robert Falotico Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
EP1750862B1 (en) * 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
CN100435755C (en) * 2004-07-27 2008-11-26 微创医疗器械(上海)有限公司 Bracket for eluting medication
EP1656941A1 (en) * 2004-11-09 2006-05-17 Clinigene International Private Limited Compositions for the treatment of diabetic nephropathy
GB0503936D0 (en) 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
CN100384416C (en) * 2006-03-20 2008-04-30 杨军 Medicinal composition for treating cerebrovascular disease
US8414909B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US8871985B2 (en) 2010-03-15 2014-10-28 Exxonmobil Chemical Patents Inc. Processes for the production of alcohols
US20150290176A1 (en) * 2012-10-12 2015-10-15 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
US10098871B2 (en) * 2013-03-15 2018-10-16 Leslie B. Gordon Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis
ES2900426T3 (en) 2013-12-31 2022-03-16 Rapamycin Holdings Llc Oral preparations and use of rapamycin nanoparticles
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CN105997940A (en) * 2016-05-11 2016-10-12 中国人民解放军第三军医大学 Inflammatory microenvironment responsive nano-drug and preparation method and application thereof
CN117224557A (en) * 2023-11-02 2023-12-15 中国人民解放军空军军医大学 Application of naringin and rapamycin in preparing medicament for treating hyperlipidemia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
ATE283687T1 (en) * 1997-06-13 2004-12-15 Wyeth Corp RAPAMYCIN FORMULATIONS FOR ORAL ADMINISTRATION
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin

Also Published As

Publication number Publication date
WO2001097809A2 (en) 2001-12-27
BR0111601A (en) 2003-07-01
US20020013335A1 (en) 2002-01-31
CA2412636A1 (en) 2001-12-27
HUP0301244A3 (en) 2005-01-28
AR028959A1 (en) 2003-05-28
EP1292302A2 (en) 2003-03-19
JP2003535899A (en) 2003-12-02
NO20026008L (en) 2002-12-13
HUP0301244A2 (en) 2003-08-28
WO2001097809A3 (en) 2002-05-10
AU6844601A (en) 2002-01-02
ZA200300418B (en) 2004-04-15
NZ523114A (en) 2004-07-30
PL365455A1 (en) 2005-01-10
IL153405A0 (en) 2003-07-06
KR20030010710A (en) 2003-02-05
CZ20024115A3 (en) 2003-06-18
NO20026008D0 (en) 2002-12-13
AU2001268446B2 (en) 2005-08-11
CN1436076A (en) 2003-08-13
MXPA02012410A (en) 2003-04-25

Similar Documents

Publication Publication Date Title
EA200300027A1 (en) METHOD OF TREATING CARDIOVASCULAR DISEASES
BRPI0307673A2 (en) methods of treating vascular disease.
DE60218493D1 (en) SUBSTITUTED 7-AZA-Ä2.2.1ÜBICYCLOHEPTANE FOR THE TREATMENT OF DISEASES
DE69833971D1 (en) METHOD FOR TREATING ALZHEIMER'S DISEASE
BR0016652A (en) Methods to inhibit cerebral amyloid angiopathy, to treat a disease state characterized by cerebral amyloid angiopathy in an individual, and to diagnose cerebral amyloid angiopathy in an individual
EA200300387A1 (en) EP4 RECEPTOR INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
MA26782A1 (en) PYRAZOLOBENZODIAZEPINES AS CDK2 INHIBITORS.
ATE526041T1 (en) METHOD FOR INHIBITING OCCULAR PROCESSES
AP2004003026A0 (en) Methods for treating ocular neovascular diseases.
BR0211905A (en) Rapamycin dialdehydes
NO971982L (en) Multipulse, multi-return, modal distance treatment for bireflex rejection
ATE286895T1 (en) SULFONYL-PYRROLIDINE DERIVATIVES SUITABLE FOR THE TREATMENT OF NEUROLOGICAL DISEASES
EA200401341A1 (en) APPLICATION OF OSTEOPROTEGERIN FOR THE TREATMENT AND / OR PREVENTION OF FIBROUS DISEASE
DK0714394T3 (en) Antipsychotic method
DE60025639D1 (en) SUBSTITUTED DIAZEPAN
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
EA200501528A1 (en) APPLICATION OF CLUSTERIN FOR THE TREATMENT AND / OR PREVENTION OF PERIPHERAL NEUROLOGICAL DISEASES
EA200100930A1 (en) METHOD OF TREATMENT COPD
WO2001087239A3 (en) Methods of affecting laminin 5 processing
EP1228756A4 (en) AGENTS FOR RELIEVING CARBONYL-INDUCED STRESS
DE60112768D1 (en) TREATMENT OF INFLAMMATORY DISEASES
DE60201440D1 (en) ARYL-8-AZABICYCLO [3.2.1] OCTANES FOR THE TREATMENT OF DEPRESSION
DE60124093D1 (en) S-methyl-dihydro-ziprasidone for the treatment of eye diseases.
EP1414478A4 (en) INHIBITION OF NEURODEGENERESCENCE
ITBO990395A0 (en) CHAIN FOR THE MANUFACTURE OF TRACKS.